BACKGROUND: Glycoprotein II b/IIIa antagonists (GPII b/IIIa-A) lower the periprocedural rate of ischemic events during high risk percutaneous coronary interventions. Their clinical impact on carotid artery stenting (CAS) remains to be determined. METHODS: We analyzed data from the Carotid Artery Stent (CAS) Registry. RESULTS: From 01/ 2000 to 06/2005 1322 CAS interventions were registered. In 94 (7.1%) procedures a GPII b/IIIa-A was used: abciximab in 8 cases (8.6%), tirofiban in 53 cases (57%) and eptifibatide in 32 cases (34.4%). The use of a GPII b/IIIa-A during CAS decreased significantly over time: from 17.6% in 2000 to 3% in 2005, p for trend <0.0001. The mean use of a GPII b/IIIa-A at the hospitals was 5.2%. More than 50% of the hospitals never used a GPII b/IIIa-A. There were no significant differences in baseline characteristics and concomitant diseases in CAS patients treated with GPII b/IIIa-A compared to those without GPII b/IIIa-A. A bilateral intervention was performed more often in patients treated with GPII b/IIIa-A (2.1 vs 0.2%, p = 0.04), a thrombus was more often visible (27 vs 12.4%, p <0.001) and an ulcer more frequently diagnosed (50 vs 37.5%, p = 0.03). There was no significant difference in the combined death or stroke rate between the two groups (5.3 vs 3.0%, p = 0.22, OR = 1.81, 95% CI: 0.69-4.72), which was confirmed by logistic regression analysis after adjusting for possible confounders (OR = 1.67, 95% CI: 0.62-4.46, p = 0.31). CONCLUSIONS: Our data neither demonstrate a significant benefit nor a significant risk with the use of GPIIb/IIIa-A during CAS. However, only an adequately sized randomized controlled clinical trial could establish the real value of GPII b/IIIa-A during CAS. Until then, considering the potential increase in cerebral hemorrhage, we should not use GPII b/ IIIa-A routinely during CAS.
BACKGROUND: Glycoprotein II b/IIIa antagonists (GPII b/IIIa-A) lower the periprocedural rate of ischemic events during high risk percutaneous coronary interventions. Their clinical impact on carotid artery stenting (CAS) remains to be determined. METHODS: We analyzed data from the Carotid Artery Stent (CAS) Registry. RESULTS: From 01/ 2000 to 06/2005 1322 CAS interventions were registered. In 94 (7.1%) procedures a GPII b/IIIa-A was used: abciximab in 8 cases (8.6%), tirofiban in 53 cases (57%) and eptifibatide in 32 cases (34.4%). The use of a GPII b/IIIa-A during CAS decreased significantly over time: from 17.6% in 2000 to 3% in 2005, p for trend <0.0001. The mean use of a GPII b/IIIa-A at the hospitals was 5.2%. More than 50% of the hospitals never used a GPII b/IIIa-A. There were no significant differences in baseline characteristics and concomitant diseases in CASpatients treated with GPII b/IIIa-A compared to those without GPII b/IIIa-A. A bilateral intervention was performed more often in patients treated with GPII b/IIIa-A (2.1 vs 0.2%, p = 0.04), a thrombus was more often visible (27 vs 12.4%, p <0.001) and an ulcer more frequently diagnosed (50 vs 37.5%, p = 0.03). There was no significant difference in the combined death or stroke rate between the two groups (5.3 vs 3.0%, p = 0.22, OR = 1.81, 95% CI: 0.69-4.72), which was confirmed by logistic regression analysis after adjusting for possible confounders (OR = 1.67, 95% CI: 0.62-4.46, p = 0.31). CONCLUSIONS: Our data neither demonstrate a significant benefit nor a significant risk with the use of GPIIb/IIIa-A during CAS. However, only an adequately sized randomized controlled clinical trial could establish the real value of GPII b/IIIa-A during CAS. Until then, considering the potential increase in cerebral hemorrhage, we should not use GPII b/ IIIa-A routinely during CAS.
Authors: Marco Roffi; Debabrata Mukherjee; Derek P Chew; Deepak L Bhatt; Leslie Cho; Mark A Robbins; Khaled M Ziada; Danielle M Brennan; Stephen G Ellis; Eric J Topol Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: G S Roubin; G New; S S Iyer; J J Vitek; N Al-Mubarak; M W Liu; J Yadav; C Gomez; R E Kuntz Journal: Circulation Date: 2001-01-30 Impact factor: 29.690
Authors: Andreas Kastrup; Klaus Gröschel; Hilmar Krapf; Bernhard R Brehm; Johannes Dichgans; Jörg B Schulz Journal: Stroke Date: 2003-02-13 Impact factor: 7.914
Authors: Robert Hofmann; Klaus Kerschner; Clemens Steinwender; Alexander Kypta; Dietmar Bibl; Franz Leisch Journal: Stroke Date: 2002-03 Impact factor: 7.914
Authors: Bernhard Reimers; Michael Schlüter; Fausto Castriota; Thilo Tübler; Nicola Corvaja; Carlo Cernetti; Raffaella Manetti; Amedeo Picciolo; Francesco Liistro; Carlo Di Mario; Alberto Cremonesi; Joachim Schofer; Antonio Colombo Journal: Am J Med Date: 2004-02-15 Impact factor: 4.965
Authors: Philipp Gruber; Martin Hlavica; Jatta Berberat; Benjamin Victor Ineichen; Michael Diepers; Krassen Nedeltchev; Timo Kahles; Luca Remonda Journal: Interv Neuroradiol Date: 2018-11-04 Impact factor: 1.610
Authors: Boris Bigalke; Peter Seizer; Tobias Geisler; Stephan Lindemann; Meinrad Gawaz; Andreas E May Journal: Clin Res Cardiol Date: 2009-03-13 Impact factor: 5.460